Monitoring the prevalence of diabetes and the quality of care using electronic health data

Similar documents
DETERMINANTS OF QUALITY IN DIABETES CARE PROCESS: THE POPULATION BASED TORINO STUDY

... Methods. Roberto Gnavi 1, Alessandro Migliardi 1, Moreno Demaria 2, Alessio Petrelli 1, Adele Caprioglio 1, Giuseppe Costa 1,3.

Declaration of Conflict of Interest. No potential conflict of interest to disclose with regard to the topics of this presentations.

... Introduction. Chiara Seghieri 1, Laura Policardo 2, Paolo Francesconi 2, Giuseppe Seghieri 2,3

SUPPLEMENTAL MATERIALS

EuroPrevent 2010 Fatal versus total events in risk assessment models

Supplementary Online Content

Appendix Identification of Study Cohorts

PATTERN OF DIABETES THERAPEUTIC PRESCRIPTION IN RURAL AND URBAN AREAS IN QUEBEC

The Diabetes Epidemic in Korea

TAHFA-South Texas HFMA Fall Symposium. Tuesday, October 17, from 10:45 AM 11:35 AM.

CLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016

Diabetes in Manitoba 1989 to 2006 R E P O R T O F D I A B E T E S S U R V E I L L A N C E

Diabetes in Manitoba: Trends among Adults

A competing risk model to estimate the hospitalisation story of a cohort of diabetic patients. The additive regression model.

PEER REVIEW HISTORY ARTICLE DETAILS VERSION 1 - REVIEW. Randi Selmer Senior Researcher Norwegian Institute of Public Health Norway

AHA Clinical Science Special Report: November 10, 2015

Seniors Health in York Region

Characteristics of Philadelphia Census Tracts with High Prostate Cancer Risk

Cardiovascular. Mathew Mercuri PhD(C), Sonia S Anand MD PhD FRCP(C)

Zhao Y Y et al. Ann Intern Med 2012;156:

A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia

Preventive Cardiology Scientific evidence

Translating Health Services Research in Sickle Cell Disease to Policy

Patterns and Cost of Health Care Transitions to Adult Care among Youth with Chronic Conditions in Ontario: A Population Based Cohort Study

Overview FLORIDA CANCER DATA SYSTEM

Data Fusion: Integrating patientreported survey data and EHR data for health outcomes research

Epidemiologic Measure of Association

A nationwide population-based study. Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD

Cancer and pharmacoepidemiology in Finland. Information sources and research possibilities

Incorporating External Data into Existing Longitudinal Studies

Supplementary Appendix

The effect of surgeon volume on procedure selection in non-small cell lung cancer surgeries. Dr. Christian Finley MD MPH FRCSC McMaster University

The prevalence of type 2 diabetes mellitus is increasing CMAJ OPEN. Research

Epidemiology of Asthma. In Wayne County, Michigan

Diabetes: Facts and Numbers, 2014

Mariza Vono Tancredi. Eliseu Alves Waldman

The TNT Trial Is It Time to Shift Our Goals in Clinical

SHORT COMMUNICATION. G. Joshy & P. Dunn & M. Fisher & R. Lawrenson

Estimates and predictors of health care costs of esophageal adenocarcinoma: a population-based cohort study

Aldo P. Maggioni, Kees Van Gool, Nelly Biondi, Renato Urso, Niek Klazinga, Roberto Ferrari, Nikolaos Maniadakis and Luigi Tavazzi.

Diabete: terapia nei pazienti a rischio cardiovascolare

PHARMO Database Network

Study period Total sample size (% women) 899 (37.7%) Warfarin Aspirin

6/5/2015. Coccidioidomycosis: An Underreported Cause of Death Arizona, Capture-Recapture

AperTO - Archivio Istituzionale Open Access dell'università di Torino

Diabetes and the Heart

New York State Department of Health Center for Environmental Health

SUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart.

Comparisons of epidemiological data on diabetic and. Incidence and Risk Factors for Stroke in Type 2 Diabetic Patients The DAI Study

The impact of diabetes on prescription drug costs: the population-based Turin study

CURRENT STRATEGIES TO OPTIMALLY TREAT PATIENTS WITH DIABETES AND CVD

Clin Microbiol Infect Feb;21(2):e11-3. doi: /j.cmi Epub 2014 Oct 29.

Supplement materials:

Cost-of-illness analysis in the EGB database

EPIDEMIOLOGY OF ARRHYTHMIAS AND OUTCOMES IN CKD & DIALYSIS KDIGO. Wolfgang C. Winkelmayer, MD, ScD Baylor College of Medicine Houston, Texas

Epidemiology of Asthma. In the Western Michigan Counties of. Kent, Montcalm, Muskegon, Newaygo, and Ottawa

Practical Case Studies in Hypertension Management. Series editor Giuliano Tocci Rome, Italy

Methodological Framework and Tools for Cross-National comparisons of Drug Utilization Data

Variations in Procedure Use

Hypoglycemia and Quality Measurement

CARDIOVASCULAR DISEASE

Research: Health Economics Impact of diabetes on healthcare costs in a population-based cohort: a cost analysis

Treatment disparities for patients diagnosed with metastatic bladder cancer in California

Measuring health care inequalities using the Census- DAD data linkage

Coronary Heart Disease in Women Go Red for Women

Why is Earlier and More Aggressive Treatment of T2 Diabetes Better?

The University of Mississippi School of Pharmacy

The Metabolic Syndrome: Is It A Valid Concept? YES

Atherosclerotic Cardiovascular Diseases: ischaemic heart disease and stroke

Deprivation and Health. A report by the National Public Health Service for Wales

9 Diabetes care. Back to contents

GSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source

Diabetes Education Columbus Community Hospital Stacy Biesel RN, CDE

Data Sources, Methods and Limitations

Cardiovascular Disease in Tennessee. Audrey M Bauer, DVM, MPH Surveillance, Epidemiology and Evaluation Tennessee Department of Health

Resistant hypertension (RH), that is, blood pressure (BP)

Supplementary Online Content

Race Original cohort Clean cohort HR 95%CI P HR 95%CI P. <8.5 White Black

Incidence of diabetes among postmenopausal breast cancer survivors

Peer Educator Networks for Diabetes and chronic NCD in Cambodia. MoPoTsyo Patient Information Centre

2/10/2016. Perspectives on the 2013 ACC/AHA Cholesterol Guidelines. Disclosures. ATP-III Update 2004

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Supplementary Information for: Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative.

Estimating RSV Disease Burden in the United States

Clinical Quality Measures Summary of Upcoming Enhancements

ESPEN Congress Florence 2008

Status of the CKD and ESRD treatment: Growth, Care, Disparities

Finland and Sweden and UK GP-HOSP datasets

LATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?

Easy. Not so Easy. Risk Assessment in the CLI Patient: Who is Likely to Benefit from Revascularization and Who is Not? 4/28/2012

Chapter 1: CKD in the General Population

Comparison of Medicare Fee-for-Service Beneficiaries Treated in Ambulatory Surgical Centers and Hospital Outpatient Departments

Applications of Pharmacoepidemiology in General Practice 2012 Joint Conference of Drug Safety Research Centres 21 November 2012, Hong Kong

Project Cohort EXPOSED GROUP

SUPPLEMENTAL MATERIAL

Risk Factors for Heart Disease

Modifying effects of dietary polyunsaturated fatty acid (PUFA) on levels of cholesterol and their implications for heart health

Survey Scottish Diabetes. Survey Monitoring Group

Transcription:

Monitoring the prevalence of diabetes and the quality of care using electronic health data Roberto Gnavi 1 Roberta Picariello 1, Graziella Bruno 2, Carlo Giorda 3, Giuseppe Costa 1,4 1 Epidemiology Unit ASL TO3, Piedmont Region; 2 Department of Internal Medicine, University of Torino; 3 Metabolism and Diabetes Unit, ASL TO5, Piedmont Region; 1,4 Department of Public Health, University of Torino, Italy EUROEPI 2010, Florence, 8 th November 2010

Background Worldwide prevalence of diabetes is estimated to be 2.8%, but in more developed societies has reached about 6% The number of people with diabetes is increasing: in the next 20 years the number of persons with diabetes will more than double (an epidemic) Mortality is up to three times greater than that of non-diabetic people To increase the survival of diabetic patients, changes in lifestyle, appropriate drug treatment, regular glycaemic control, and the continuous surveillance of health status are necessary Surveillance systems monitoring the occurrence of the disease over geographical areas and time and the quality of care received by persons with diabetes are needed to allow timely identification of critical cal points and rational planning of interventions

Objectives To report a selection of results from a population-based surveillance program, implemented in the city of Turin (900,000 inhabitants) Italy, based on administrative databases and aimed to monitor the occurrence of diabetes and the quality of care

Population with diabetes: data sources Exemption from payment: exemption from payment of drugs and laboratory tests because of a diagnosis of DM Regional Drug Prescriptions Database: All residents who had at least two prescriptions of antidiabetic drugs (ATC A10A and A10B) in 2003 Hospital Discharge Database: All residents discharged with a primary or secondary diagnosis of diabetes (ICD9 CM 250) from 1995 to 2002

Distribution of persons with diabetes by source of ascertainment 31 st July 2003 Exemption from payment for drugs 27.417 4.837 3.068 4.780 Hospital discharges 19.043 (1995-2002) 10.157 9.355 1.185 1.038 n = 34420 Drug Prescriptions Turin Population Register 21.735 (at least two prescriptions in to 2003) include people alive and resident on 31 st July 2003 to determine individual educational level

Prevalence of diabetes in residents of Turin; 2003 Three sources Adjusted for undercount (capture recapture) n % n % difference (%) Gender Donne 17135 3,66 21810 4,66 78,6 Uomini 17285 4,02 21035 4,90 82,2 Age < 65 12907 1,86 16718 2,40 77,2 65 74 11591 10,27 14222 12,60 81,5 > 75 9922 11,10 11905 13,31 83,4 ALL 34420 3,83 42845 4,77 80,4

Prevalence of diabetes by educational level in residents > 20 ys. old; Turin 2003 Men Women Prevalence (%) PRR* Prevalence (%) PRR* (95% CI) (95% C I) (95% C I) (95% C I) Educational level High 4.49 1. 00 2.55 1.00 (4.35-4.63) (2.44-2.67) Medium 5.67 1.26 3.95 1.55 (5.52-5.82) (1.21-1.32) (3.84-4.06) (1.47-1.63) Low 10.41 2.32 8.80 3.45 (10.2-10.6) (2.23-2.41) (8.61-8.98) (3.28-3.62) * Adjusted for age Nutr Metab Cardiovasc Dis 2008; 18:678-682

To monitor the quality of the process of care of diabetes Regional Register Diabetes 27.417 3.068 residents 4.837 in (14%) 4.780 (14%) Hospital discharges 19.043 34420 residents in Turin with diabetes 10.157 1.038 1.185 (3%) Torino Population Register Drug Prescriptions 21.735 to include people alive on 31st July 2003 to determine individual educational level to determine census tract median income 1 year Regional data base of ambulatory and outpatient care Drug prescriptions Hospital discharges therapy (insulin, oral drugs, diet only) circulatory disease

Laboratory test and outpatient consultations in persons with diabetes in Turin Test 1 year % 2 year % Glycosylated Hb 71.0 80.1 Cholesterol 64.7 80.3 Microalbuminuria 31.0 46.8 Eye examination 23.6 37.9 ECG 33.3 50.6 Diabetologist 67.5 73.3 GCI * 35.8 55.0 * Guidelines Composite Indicator A1C + two among eye examination / cholesterol / microalbumiuria

Laboratory test and outpatient consultations in persons with diabetes in Turin Gender Eye A1C Cholesterol M.albuminuria Diabetologist examination ECG GCI PR PR PR PR PR PR PR women 1 1 1 1 1 1 1 men 1,01 0,99 1,04 1,01 1,05 1,08 1,02 Age 21-44 1 1 1 1 1 1 1 45-54 0,99 1,11 0,98 1,08 0,96 1,48 1,03 55-64 1,08 1,21 1,05 1,15 0,98 1,81 1,10 65-74 1,11 1,28 0,95 1,17 0,91 1,94 1,04 >=75 0,96 1,01 0,56 0,97 0,55 1,55 0,62 Educational level high 1 1 1 1 1 1 1 medium 1,05 1,04 1,02 1,08 1,11 1,16 1,05 low 1,04 1,00 0,98 1,11 1,08 1,18 1,00 Treatment diet only 1 1 1 1 1 1 1 oral drugs 1,74 1,35 1,97 1,83 1,84 1,36 1,98 insulin 1,84 1,35 2,18 1,98 2,11 1,42 2,21 Diabetes Care 2009;32:1980-1985

Adherence to guidelines in persons with diabetes in Turin by health district of residence; Prevalence Ratios Prevalence Ratio

To monitor the outcomes of care of diabetes Regional Register Diabetes 27.417 4.837 3.068 4.780 (14%) (14%) 10.157 33,036 residents 1.038 Hospital discharges 19.043 residents with diabetes (1 st january 2002) 1.185 (3%) Torino Population Register Drug Prescriptions 21.735 to include people alive on 31st July 2003 to determine individual educational level to determine census tract median income 4 years f.u. MORTALITY All causes Chd Stroke Cancer AMPUTATIONS INCIDENCE Ami Stroke

Outcomes: Standard. Mortality/Incidence Ratio (ref. without diabetes) Men Women n SMR/SIR n SMR/SIR Mortality All 2755 168 2616 175 Circulatory diseases 1012 169 1134 163 CHD 425 214 367 238 Cerebrovascular disease 263 156 321 129 Cancer 835 140 521 140 Incidence Ami 658 195 540 290 Stroke 525 182 535 177 Amputations 113 1022 66 968

Outcomes: mortality/incidence by educational level in diabetic and non diabetic men Diabetics Non diabetics Educational level Medium Elementary Medium Elementary HR HR p for trend HR HR p for trend Mortality All 1.18 1.22 0.001 1.25 1.42 <0.001 Circulatory diseases 1.26 1.21 0.141 1.14 1.22 <0.001 Incidence AMI 1.06 1.05 0.863 1.27 1.33 <0.001 stroke 0.94 1.16 0.087 1.33 1.47 <0.001 Amputations 1.33 1.28 0.450 2.10 2.62 0.002

Outcomes: mortality/incidence by educational level in diabetic and non diabetic women Diabetics Non diabetics Educational level Medium Elementary Medium Elementary HR HR p for trend HR HR p for trend Mortality All 1.02 1.03 0.987 1.07 1.16 <.0001 Circulatory diseases 1.14 1.05 0.659 1.06 1.17 <.0001 Incidence AMI 1.13 1.06 0.909 1.14 1.23 0.002 stroke 0.96 1.08 0.434 1.24 1.38 <.0001 Amputations 0.63 0.30 0.0002 1.20 1.24 0.744

Conclusions It is possible, with administrative data, to identify large cohorts of persons with known diabetes, to calculate the prevalence of the disease, and to monitor prospectively, at population level, several indicators that are used internationally to asses the quality of care This allows, in a simple way and at very low cost, to monitor the epidemiology of diabetes and to identify some strengths and weakness of the care system

Thank you for your attention Roberto.gnavi@epi.piemonte.it